These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 29976748

  • 1. CD16+NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice.
    Williams BA, Wang XH, Leyton JV, Maghera S, Deif B, Reilly RM, Minden MD, Keating A.
    Haematologica; 2018 Oct; 103(10):1720-1729. PubMed ID: 29976748
    [Abstract] [Full Text] [Related]

  • 2. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.
    Busfield SJ, Biondo M, Wong M, Ramshaw HS, Lee EM, Ghosh S, Braley H, Panousis C, Roberts AW, He SZ, Thomas D, Fabri L, Vairo G, Lock RB, Lopez AF, Nash AD.
    Leukemia; 2014 Nov; 28(11):2213-21. PubMed ID: 24705479
    [Abstract] [Full Text] [Related]

  • 3. Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131- phenotype of the leukemia stem cell population.
    Leyton JV, Hu M, Gao C, Turner PV, Dick JE, Minden M, Reilly RM.
    J Nucl Med; 2011 Sep; 52(9):1465-73. PubMed ID: 21816968
    [Abstract] [Full Text] [Related]

  • 4. Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.
    Hutmacher C, Volta L, Rinaldi F, Murer P, Myburgh R, Manz MG, Neri D.
    Leuk Res; 2019 Sep; 84():106178. PubMed ID: 31326578
    [Abstract] [Full Text] [Related]

  • 5. Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123.
    Morgan MA, Kloos A, Lenz D, Kattre N, Nowak J, Bentele M, Keisker M, Dahlke J, Zimmermann K, Sauer M, Heuser M, Schambach A.
    Viruses; 2021 Jul 14; 13(7):. PubMed ID: 34372571
    [Abstract] [Full Text] [Related]

  • 6. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.
    Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L, Guthridge MA, Thomas D, Barry EF, Boyd A, Gearing DP, Vairo G, Lopez AF, Dick JE, Lock RB.
    Cell Stem Cell; 2009 Jul 02; 5(1):31-42. PubMed ID: 19570512
    [Abstract] [Full Text] [Related]

  • 7. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells.
    Arvindam US, van Hauten PMM, Schirm D, Schaap N, Hobo W, Blazar BR, Vallera DA, Dolstra H, Felices M, Miller JS.
    Leukemia; 2021 Jun 02; 35(6):1586-1596. PubMed ID: 33097838
    [Abstract] [Full Text] [Related]

  • 8. Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1.
    Ernst D, Williams BA, Wang XH, Yoon N, Kim KP, Chiu J, Luo ZJ, Hermans KG, Krueger J, Keating A.
    Blood Cancer J; 2019 Jan 15; 9(2):6. PubMed ID: 30647406
    [Abstract] [Full Text] [Related]

  • 9. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S, Oberschmidt O, Morgan M, Dahlke J, Arseniev L, Huppert V, Granzin M, Gardlowski T, Matthies N, Soltenborn S, Schambach A, Koehl U.
    Hum Gene Ther; 2017 Oct 15; 28(10):897-913. PubMed ID: 28810809
    [Abstract] [Full Text] [Related]

  • 10. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
    Chen Y, You F, Jiang L, Li J, Zhu X, Bao Y, Sun X, Tang X, Meng H, An G, Zhang B, Yang L.
    Oncotarget; 2017 Jun 06; 8(23):37128-37139. PubMed ID: 28415754
    [Abstract] [Full Text] [Related]

  • 11. Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.
    Han L, Jorgensen JL, Brooks C, Shi C, Zhang Q, Nogueras González GM, Cavazos A, Pan R, Mu H, Wang SA, Zhou J, Ai-Atrash G, Ciurea SO, Rettig M, DiPersio JF, Cortes J, Huang X, Kantarjian HM, Andreeff M, Ravandi F, Konopleva M.
    Clin Cancer Res; 2017 Jul 01; 23(13):3385-3395. PubMed ID: 28096272
    [Abstract] [Full Text] [Related]

  • 12. AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells.
    Fan D, Li Z, Zhang X, Yang Y, Yuan X, Zhang X, Yang M, Zhang Y, Xiong D.
    J Hematol Oncol; 2015 Feb 28; 8():18. PubMed ID: 25879549
    [Abstract] [Full Text] [Related]

  • 13. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
    Christodoulou I, Ho WJ, Marple A, Ravich JW, Tam A, Rahnama R, Fearnow A, Rietberg C, Yanik S, Solomou EE, Varadhan R, Koldobskiy MA, Bonifant CL.
    J Immunother Cancer; 2021 Dec 28; 9(12):. PubMed ID: 34896980
    [Abstract] [Full Text] [Related]

  • 14. A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia.
    He SZ, Busfield S, Ritchie DS, Hertzberg MS, Durrant S, Lewis ID, Marlton P, McLachlan AJ, Kerridge I, Bradstock KF, Kennedy G, Boyd AW, Yeadon TM, Lopez AF, Ramshaw HS, Iland H, Bamford S, Barnden M, DeWitte M, Basser R, Roberts AW.
    Leuk Lymphoma; 2015 May 28; 56(5):1406-15. PubMed ID: 25248882
    [Abstract] [Full Text] [Related]

  • 15. Targeting CD157 in AML using a novel, Fc-engineered antibody construct.
    Krupka C, Lichtenegger FS, Köhnke T, Bögeholz J, Bücklein V, Roiss M, Altmann T, Do TU, Dusek R, Wilson K, Bisht A, Terrett J, Aud D, Pombo-Villar E, Rohlff C, Hiddemann W, Subklewe M.
    Oncotarget; 2017 May 30; 8(22):35707-35717. PubMed ID: 28415689
    [Abstract] [Full Text] [Related]

  • 16. Cytotoxicity Assessment and Apoptosis-related Gene Profiling of Antibody Treated Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) Cancerous Cell Lines.
    Habibi-Anbouhi M, Kafi Z, Ghazizadeh L, Kharazi S, Behdani M, Faraji F, Shokrgozar MA.
    Iran J Allergy Asthma Immunol; 2019 Oct 30; 18(6):679-687. PubMed ID: 32245312
    [Abstract] [Full Text] [Related]

  • 17. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
    Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, Hoffman L, Aguilar B, Chang WC, Bretzlaff W, Chang B, Jonnalagadda M, Starr R, Ostberg JR, Jensen MC, Bhatia R, Forman SJ.
    Blood; 2013 Oct 31; 122(18):3138-48. PubMed ID: 24030378
    [Abstract] [Full Text] [Related]

  • 18. The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors.
    Mani R, Goswami S, Gopalakrishnan B, Ramaswamy R, Wasmuth R, Tran M, Mo X, Gordon A, Bucci D, Lucas DM, Mims A, Brooks C, Dorrance A, Walker A, Blum W, Byrd JC, Lozanski G, Vasu S, Muthusamy N.
    Haematologica; 2018 Aug 31; 103(8):1288-1297. PubMed ID: 29773600
    [Abstract] [Full Text] [Related]

  • 19. Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
    Han YC, Kahler J, Piché-Nicholas N, Hu W, Thibault S, Jiang F, Leal M, Katragadda M, Maderna A, Dushin R, Prashad N, Charati MB, Clark T, Tumey LN, Tan X, Giannakou A, Rosfjord E, Gerber HP, Tchistiakova L, Loganzo F, O'Donnell CJ, Sapra P.
    Clin Cancer Res; 2021 Jan 15; 27(2):622-631. PubMed ID: 33148666
    [Abstract] [Full Text] [Related]

  • 20. Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123.
    Gauthier L, Virone-Oddos A, Beninga J, Rossi B, Nicolazzi C, Amara C, Blanchard-Alvarez A, Gourdin N, Courta J, Basset A, Agnel M, Guillot F, Grondin G, Bonnevaux H, Bauchet AL, Morel A, Morel Y, Chiron M, Vivier E.
    Nat Biotechnol; 2023 Sep 15; 41(9):1296-1306. PubMed ID: 36635380
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.